ED
NKTR icon

Exane Derivatives’s Nektar Therapeutics NKTR Stock Holding History

Exane Derivatives’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-190
Closed -$50.8K – 730
2020
Q1 		$50.8K Sell
190
-750
-80% -$232K 0.01% 351
2019
Q4 		$331K Sell
940
-1,063
-53% -$308K 0.06% 203
2019
Q3 		$547K Buy
2,003
+893
+80% +$327K 0.1% 159
2019
Q2 		$592K Sell
1,110
-309
-22% -$155K 0.1% 154
2019
Q1 		$715K Buy
+1,419
New +$841K 0.14% 134

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Exane Derivatives's NKTR Position: Q2 2020 in Review

Exane Derivatives sold out of Nektar Therapeutics (NKTR) in Q2 2020, closing a stake of 190 shares — an estimated $50.8K sold.

Exane Derivatives first reported a position in NKTR in Q1 2019 and held it in 5 quarters. The position peaked at $715K in Q1 2019. 259 funds tracked by Wall St. Rank hold NKTR as of Q2 2020.

  • Exane Derivatives reported no remaining Nektar Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Exane Derivatives sold 190 Nektar Therapeutics shares in Q2 2020, an estimated $50.8K.
  • Exane Derivatives first reported a position in Nektar Therapeutics in Q1 2019 and held it in 5 quarters.
  • Exane Derivatives's Nektar Therapeutics position peaked at $715K in Q1 2019.
  • 259 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2020.

Based on Exane Derivatives's 13F filing for Q2 2020, filed 10 Jul 2020.